Recent preclinical data published in Molecular Therapy suggest the company may be closer than ever to answering that question. Its platform did not emerge from a single discovery programme, but from a sequence of acquisitions that brought together the key ingredients for in vivo cell engineering: mRNA payloads, lipid nanoparticle delivery, and targeted immune-cell guidance. Across big pharma, companies are increasingly assembling in vivo CAR-T platforms piece by piece, raising a broader question about whether the next generation of cell therapy will be built in-house, or bought.
RQ Bio raises $115m for long-acting flu antibody
Latest NewsLondon’s RQ Bio, a private biotech developing long-acting antibody therapeutics to prevent flu, has raised $115 million (£85.5 million/€101 million) in its Series A financing.
Thalia buys Sanmirna, becomes a clinical-stage RNA company
Latest NewsThalia Therapeutics is acquiring Sanmirna Therapeutics for an initial £3.675 million and up to £13 million in milestone payments, adding the clinical-stage acute myeloid leukemia (AML) candidate miRisten and transforming the company from a preclinical platform into a clinical-stage RNA therapeutics company.
Merck launches build-to-buy Saturnus Bio with $50m
Latest NewsMerck KGaA has partnered with Versant Ventures to launch Saturnus Bio, a new biotech developing precision medicines for rare genetic cardiomyopathies.
TRIMTECH extends seed round to $47M for protein degradation drugs
Latest NewsUK-based TRIMTECH Therapeutics has raised an additional $14 million, bringing its total seed financing to $47 million.
Indivumed, ready to set sail to the clinic
slider, Sponsored PublicationsWith the separation from the biobank service business, Hamburg-based Indivumed has repositioned itself as a therapeutics biotech. Its earlier work remains the core of its medical knowledge and the source of novel targets. To advance the already pre-validated selection more quickly, the company is now looking for partners. The response has been strong, say Matthias Evers and Hartmut Juhl in conversation with European Biotechnology Magazine.
After FDA rejection, Sanofi’s BTK inhibitor wins EU approval
Latest NewsSanofi’s Cenrifki (tolebrutinib) has been approved in the EU as the first disability-targeting medicine for adults with secondary progressive multiple sclerosis (SPMS) without relapses in the previous two years.
Can Sanofi buy its way into in vivo CAR-T?
Background, Latest NewsRecent preclinical data published in Molecular Therapy suggest the company may be closer than ever to answering that question. Its platform did not emerge from a single discovery programme, but from a sequence of acquisitions that brought together the key ingredients for in vivo cell engineering: mRNA payloads, lipid nanoparticle delivery, and targeted immune-cell guidance. Across big pharma, companies are increasingly assembling in vivo CAR-T platforms piece by piece, raising a broader question about whether the next generation of cell therapy will be built in-house, or bought.
Bionyra launches with $165m, France’s largest biotech Series A
Latest NewsWith an unusually strong fundraising trajectory, Paris-based Bionyra Pharma emerged from stealth today with financing that marks the largest life sciences biopharma Series A round in Europe this year and the largest of all time in France. The company develops next-generation biologics for immune-mediated inflammatory diseases, including inflammatory bowel disease (IBD) and atopic dermatitis.
BioArctic signs potential $1bn Alzheimers research deal with Eli Lilly
Latest NewsBioArctic AB has signed a research and collaboration agreement with Eli Lilly potentially worth $1 billion, researching a new treatment combining BioArctic’s proprietary BrainTransporter technology with an undisclosed Lilly drug candidate in neurodegeneration.
Theranostics as potential novel therapeutic pillar in oncology
Sponsored PublicationsSee-and-Treat Concept using Radioactive Smart Probes: Professor Rudolf Werner provides an overview of established and future indications in clinical practice, highlighting advances in theranostics and their growing impact on precision oncology.